David Moss
Profile
David Moss worked as a Research Director at Cambridge Biostability Ltd.
and as a Project Director at Xenetic Biosciences (UK) Ltd.
in 2009.
Former positions of David Moss
Companies | Position | End |
---|---|---|
Cambridge Biostability Ltd.
Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Chief Tech/Sci/R&D Officer | 2010-06-15 |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Cambridge Biostability Ltd.
Cambridge Biostability Ltd. Pharmaceuticals: MajorHealth Technology Cambridge Biostability Ltd. manufactures vaccines and drugs. The firm's two platforms VitRIS and HydRIS offers pharmaceuticals, vaccines, and other biological products in thermo-stable, instantly-injectable formats. The company was founded by Dr Bruce Roser in 2003 and is headquartered in UK. | Health Technology |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- David Moss